Antiendotoxin activity of cationic peptide antimicrobial agents

Infection and Immunity

Volumn 64, Issue 12, 1996, Pages 4922-4927

  Gough, Monisha ^a   Hancock, Robert E W ^a   Kelly, Niamh M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; MBI 27; MBI 28; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENETIC ENGINEERING; GRAM NEGATIVE BACTERIUM; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK;

EID: 0029824838     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.12.4922-4927.1996     Document Type: Article

References (42)

1. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Allred, J. E. Pennington, and J. C. Wherry. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome, JAMA 273:934-941.
2. Amsterdam, D. 1991. Susceptibility testing of antimicrobials in liquid media, p. 72-78. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins Co., Baltimore.
3. Baumgartner. J. D., D. Heumann, J. Geriln, P. Weinbreck, G. E. Grau, and M. P. Glauser. 1990. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induccd tumor necrosis factor and interleukin 6. J. Exp. Med. 171:889-896.
4. Beutler, B., l. W. Milsark, and A. Cerami. 1985. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 135:3972-3977.
5. Beutler, B., I. W. Milsark, and A. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
6. Bortolussl, R., P. Ferrieri, B. Björkstén, and P. G. Quie. 1979. Capsular Kl polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect. Immun. 25:293-298.
7. Brandtzaeg, P., P. Kierulf, P. Gaustrad, A. Skulberg, J. N. Bruun, S. Halvorsen, and E. Surensen. 1989. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J. Infect. Dis. 159:195-204.
8. Budavari, S., M. O'Neil, A. Smith, and P. E. Heckelman. 1989. Merck Index, 11th ed. Merck and Co., Inc., Rahway, N.J.
9. Burd, R. S., C. S. Cody, and E. L. Dunn (ed.). 1992. Immunotherapy of gram-negative bacterial sepsis. R. G. Landes Co., Austin. Tex.
10. Christ, W. J., O. Asano, A. L. C. Robidoux, M. Perez, Y. Wang, G. R. Dubuc, W. E. Gavin, L. D. Hawkins, P. D. McGuinness, M. A. Mullarkey, M. D. Lewis, Y. Kishi, T. Kawata, J. R. Bristol, J. R. Rose, D. P. Rossignal, S. Kobayashi, I. Hishinuma, A. Kimura, N. Asakawa, K. Katayama, and I. Yamatsu. 1995. E5531, a pure endotoxin antagonist of high potency. Science 268:80-83.
11. Cehen, J., and J. S. McConnell. 1985. Antibiotic-induced endotoxin release. Lancet 11:1069-1070.
12. Cross, A. S., and S. Opal. 1994. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? Endotox. Res, 1:57-61.
13. Cryz, S. J., Jr., E. Purer, and R. Germanier. 1983. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect. Immun. 39:1067-1071.
14. Darveau, R. P., and R. E. W. Hancock. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Psedomonas aeruginosa and Salmonella typhimurium. J. Bacteriol. 155:831-838.
15. Freudenberg, M. A., O. Keppler, and C. Galinos. 1986. Requirement for lipopolysaccharide response in macrophages in galactosamine-induced sensilization to endotoxin. Infect. Immun. 51:891-897.
16. Galanos, C., M. A. Freudenberg, and W. Reutler. 1979. Galactosamine induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76:5939-5943.
17. Greenman, R. L., R. M. Schein, M. A. Martin, R. P. Wenzel, N. R. MacIntyre, G. Emmanuel, H. Chmel, K. B. Kohler, M. McCarthy, J. Plouffe, J. A. Russell, and the XOMA Sepsis Study Group. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102.
18. Hanasawa, K., T. Tani, and M. Kodama. 1989. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg. Gynecol. Obstct. 168:323-331.
19. Hancock, R. E. W., T. Falla, and M. H. Brown. 1995. Cationic bacterial peptide. p. 135-175. In R. K. Poole (ed.), Advances in microbial physiology. Academic Press Ltd., London.
20. Kelly, N. M., L. Young, and A. S. Cross. 1991. Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaceharide phenotypes. Infect. Immun. 59:4491-4496.
21. Levy, O., C. E. Ool, J. Weiss, R. I. Lehrer, and P. Elsbach. 1994. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin. Invest. 94:672-682.
22. 23). J. Biol. Chem. 269:1865-1872.
23. Marra, M. N., C. G. Wilde, M. S. Collins, J. L. Snable, M. B. Thornton, and R. W. Scott. 1992. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J. Immunol. 148:532-537.
24. Marra, M. N., C. G. Wilde, J. E. Griffith, J. L. Snable, and R. W. Scott. 1990. Bactericidal/permeability-increasing protein has endotoxin neutralizing activity. J. Immunol. 144:662-666.
25. Mathlson, J. C., E. Wolfson, and R. J. Ulevitch. 1988. Participation of tumor necrosis factor in the mediation of gram-negative bacteria lipopdysaccharide-induccd injury in rabbits. J. Clin. Invest. 88:1925-1937.
26. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
27. Moore, R. A., N. C. Bates, and R. E. W. Hancock. 1986. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob. Agents Chemother. 29:495-500.
28. Piers, K. L., M. H. Brown, and R. E. W. Hancock. 1994. Improvement of outer membrane-permeabilizing lipopolysaccharidc-hinding activities of an antimicrobial cationic peptide by c-terminal modification. Amimicrob. Agents Chemother. 38:2311-2316.
29. Piers, K. L., M. H. Brown, and R. E. W. Hancock. 1993. Recombinant DNA procedures for producing small antimicrobial calionic peptides in bacteria. Gene 134:7-13.
30. Piers, K. L., and R. E. W. Hancock. 1994. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Mol. Microbiol. 12:951-958.
31. Prins, J. M., E. J. Kuljper, M. L. Mevissen, P. Speelman, and S. J. Van Deventer. 1995. Release of tumor necrosis factor and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 63:2236-2242.
32. Rogy, M. A., L. L. Moldawer, H. S. Oldenburg, W. A. Thompson, W. J. Montegut, S. A. Stackpole, A. Kumar, M. A. Palladino, M. N. Marra, and S. F. Lowry. 1994. Anti-endotoxin therapy in primate bacteremia with HA-1A and BP1. Ann Surg. 220:77-85.
33. Rogy, M. A., H. S. Oldenburg, S. E. Calvano, W. J. Montegut, S. A. Stackpole, K. J. Van Zee, M. N. Marra, R. W. Scott, J. J. Seilhammer, L. L. Moldawer, and S. F. Lowry. 1994. The role of bacterial/pcrmeabilily-increasing protein in the treatment of primate bacteremia and septic shock. J. Clin. Immunol. 14:120-133.
34. Shenep, J. L., R. P. Barton, and K. A. Mogan. 1985. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J. Infect. Dis. 151:1012-1018.
35. Stokes, D. C. J. L. Shenep, M. Fishman, W. K. Hildner, G. K. Bysani, and K. Rufus, 1989. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor from alveolar macrophages. J. Infect. Dis. 160:52-57.
36. Tracey, K. J., Y. Fong, D. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia, Nature (London) 330:662-664.
37. Van Deventer, S. J. H., H. R. Buller, J. W. TenCate, A. Sturk, and W. Paul. 1988. Endotoxemia: an early predictor of septicaemia in febrile patients. Lancet 1:605-608.
38. Van Zee, K. J., T. Kohno, E. Fischer, C. S. Rock, L. L. Moldawer, and S. F. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89:4845-4849.
39. Warren, H. S., S. F. Amalo, C. Fitting, K. M. Black, P. M. Loiselle, M. S. Pasternack, and J. M. Cavaillon. 1493. Assessment or ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177:89-97.
40. Westphal, O., and K. Jann, 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further application of the procedure, p. 83-91, In R. L. Whistler (ed)., Methods in carbohydrate chemistry, vol. 5. Academic Press, Inc., New York.
41. Wherry, J., R. Wenzel, E. Abraham, R. Allred, R. Balk, R. Bone, H. Levy, S. Nasraway, T. Perl, H. Silverman, R. Wnderink, and the TNF MAb Study Group. 1993. A controlled randomized double blind clinical trial of monoclonal antibody to tumor necrosis factor (TNF MAb) in patients with sepsis syndrome. Chest 104:3S.
42. Ziegler, E. J., C. J. Fisher, Jr., C. L. Sprung, R. C. Straube, J. C. Sadoff, G. E. Foulke, C. H. Wortel, M. P. Fink, R. P. Dellinger, N. N. H. Teng, I. E. Allen, H. J. Berger, G. L. Knatterud, A. F. LoBuglio. C. R. Smith, and the HA-1A Sepsis Study Group. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324: 429-432.